Fig. 3: Detailed overview of the qualifying and co-occurring mutational profile for individual patients. | British Journal of Cancer

Fig. 3: Detailed overview of the qualifying and co-occurring mutational profile for individual patients.

From: A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations

Fig. 3: Detailed overview of the qualifying and co-occurring mutational profile for individual patients.The alternative text for this image may have been generated using AI.

Includes select clinical outcomes—best response, progression-free survival ≥ 6 months, time to progression 2 to time to progression 1 ratio, TTP2/TTP1 ≥ 1.3) by treatment group; clinical parameters—cancer histotype, no. of prior lines of treatment, prior platinum; and biomarkers of interest—genomic alteration type, tumour mutational burden, and PD-L1 status. HR homologous recombination repair, NLR neutrophil-lymphocyte ratio, PFS progression-free survival, TTP time to progression, TMB tumour mutational burden.

Back to article page